日本の免疫蛍光アッセイ市場の評価：製品別、タイプ別、用途別、エンドユーザー別、地域別、機会および予測、2018～2032年

日本の免疫蛍光アッセイ市場は、2025～2032年度の予測期間中にCAGR 5.67％を記録し、2024年度の3億185万米ドルから2032年度には4億6,913万米ドルに成長すると予測されます。市場の成長を後押ししているのは、高齢化社会の急速な拡大、ヘルスケア分野の強化に向けた投資の増加、慢性疾患や感染症の流行拡大です。ヘルスケア・インフラの整備に向けた日本政府の重点的な取り組みと投資の増加も、日本の免疫蛍光アッセイの市場成長を支えるものと予想されます。

心血管疾患、感染症、自己免疫疾患の脅威の増大は、日本の免疫蛍光アッセイ市場規模を押し上げる主な要因の一つです。2024年3月にJournal of Clinical Rheumatology（JCR）に掲載された研究によると、日本における多発性硬化症、バセドウ病（GD）、橋本甲状腺炎（HT）、関節リウマチ（RA）などの自己免疫疾患の相対リスクは2.32でした。免疫蛍光アッセイは、疾患の進行のモニタリング、研究開発活動、疾患の早期診断・発見、公衆衛生への取り組みの効果的な推進において重要な役割を果たしています。さらに、市場の主要企業と大手製薬企業との戦略的提携により、新規診断ソリューションの提供が強化され、市場に有利な成長機会がもたらされています。

さらに、免疫蛍光アッセイは、ワクチンやモノクローナル抗体を含むバイオ医薬品の品質管理にも応用され、タンパク質の適切なアセンブリー、機能、フォールディングを保証しています。このような免疫蛍光アッセイの多様な用途は、今後数年間、同国の市場需要を高めると期待されています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 日本の免疫蛍光アッセイ市場の見通し、2018年～2032年

• 市場規模の分析と予測
  • 金額別
• 市場シェア分析と予測
  • 製品別
    • 抗体
    • キットと試薬
    • 機器
    • 消耗品およびアクセサリ
  • タイプ別
    • 間接免疫蛍光法
    • 直接免疫蛍光法
  • 用途別
    • がん
    • 感染症
    • 心血管疾患
    • 自己免疫疾患
    • その他
  • エンドユーザー別
    • 学術調査機関
    • 製薬・バイオテクノロジー企業
    • 契約調査機関
    • 病院および診断センター
  • 地域別
    • 北部（北海道・東北）
    • 中部（関東・中部）
    • 南部（関西、中国、四国、九州・沖縄）
  • 市場シェア分析（上位5社およびその他- 金額別、2024年度）、企業別
• 市場マップ分析、2024年度
  • 製品別
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 地域別

第5章 需要供給分析

第6章 バリューチェーン分析

第7章 ポーターのファイブフォース分析

第8章 PESTLE分析

第9章 価格分析

第10章 市場力学

• 市場促進要因
• 市場の課題

第11章 市場の動向と発展

第12章 規制枠組みとイノベーション

• 臨床試験
• 規制当局の承認

第13章 特許の情勢

第14章 ケーススタディ

第15章 競合情勢

• 市場リーダー上位5社の競合マトリックス
• 上位5社のSWOT分析
• 市場上位10社の主要企業の情勢
  • Immuno-Biological Laboratories Co, Ltd.
  • 会社概要
  • 主要経営陣
  • 製品とサービス
  • 財務状況（報告通り）
  • 主な市場フォーカスと地理的プレゼンス
  • 最近の動向/コラボレーション/ パートナーシップ/合併と買収
  • Euroimmun Japan Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • Abcam plc
  • PerkinElmer Inc.
  • Merck KGaA
  • Cell Signaling Technology, Inc.
  • Danaher Corporation
  • Sino Biological, Inc.

上記の企業は市場シェアに基づいて注文を保留しておらず、調査作業中に入手可能な情報に基づいて変更される可能性があります。

第16章 戦略的提言

第17章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Japan Immunofluorescence Assays Market, By Value, In USD Million, FY2018-FY2032F
• Figure 2. Japan Immunofluorescence Assays Market Share (%), By Products, FY2018-FY2032F
• Figure 3. Japan Immunofluorescence Assays Market Share (%), By Type, FY2018-FY2032F
• Figure 4. Japan Immunofluorescence Assays Market Share (%), By Application, FY2018-FY2032F
• Figure 5. Japan Immunofluorescence Assays Market Share (%), By End-user, FY2018-FY2032F
• Figure 6. Japan Immunofluorescence Assays Market Share (%), By Region, FY2018-FY2032F
• Figure 7. By Products Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 8. By Type Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 9. By Application Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 10. By End-user Map-Market Size (USD Million) & Growth Rate (%), FY2024

By Region Map-Market Size (USD Million) & Growth Rate (%), FY2024

Japan immunofluorescence assays market is projected to witness a CAGR of 5.67% during the forecast period FY2025-FY2032, growing from USD 301.85 million in FY2024 to USD 469.13 million in FY2032. The market's growth is bolstered by the rapid expansion of the aging population, increasing investments towards enhancing the healthcare sector, and the growing prevalence of chronic and infectious diseases. The increasing focus of the government of Japan towards the improvement of the healthcare infrastructure coupled with the increasing investments are also expected to support the market growth of Japan's immunofluorescence assays.

The growing threat of cardiovascular, infectious, and autoimmune diseases is one of the major factors boosting the Japan immunofluorescence assays market size. According to a study published in the Journal of Clinical Rheumatology (JCR) in March 2024, the relative risk of autoimmune diseases, such as multiple sclerosis, Graves' disease (GD) and Hashimoto's thyroiditis (HT), and rheumatoid arthritis (RA), in Japan was 2.32. Immunofluorescence assays play a crucial role in monitoring the progression of the diseases, research and development activities, early diagnosis and detection of diseases, and effective progression of public health initiatives. Moreover, strategic collaboration between leading players of the market and major pharmaceutical companies to bolster the availability of novel diagnostic solutions further provides lucrative growth opportunities to the market.

Additionally, immunofluorescence assays are also deployed for quality control of biopharmaceutical products, including vaccines and monoclonal antibodies to ensure proper assembly, function, and folding of proteins. Such diverse applications of immunofluorescence assays are expected to bolster the country's market demand in the coming years.

Rapid Expansion of the Aging Population Bolsters Market's Demand

The increasing requirement for immunofluorescence assays can be attributed to the rapid growth of the molecular biology and immunology sectors because of rising investments towards the development of personalized and age-related healthcare diagnostic and treatment solutions. As per the estimates of the World Economic Forum, more than one in ten people in Japan are eighty or older as of September 2023. As the population ages, it becomes more prone to various diseases and disorders, augmenting the requirement for various diagnostic tools and techniques to ensure that the conditions are detected in a time-efficient manner and the patients receive adequate care. Additionally, the older population also requires frequent visits to doctors and health checkups to ensure the proper functioning of all the organs, further augmenting the requirement for immunofluorescence assays.

Increasing Investments in the Healthcare Industry Supports Market Expansion

The government of Japan is adopting a multifaceted approach to increase the country's contribution to the global healthcare industry, support the digital transformation of the healthcare sector, and enhance the healthcare services provided to the patient population. Increasing investments in technological innovations in medical technologies are aiding in improving the specificity and sensitivity of immunofluorescence assays, increasing their reliability for the detection of low-abundance biomarkers. The Japanese government is expected to hasten the implementation of digital health technologies in response to challenges such as an ageing population and rising healthcare costs. These include solutions such as telemedicine, electronic health records, and AI-driven diagnostics.

Notably, partnerships are emerging to enhance these digital integrations. For instance, a joint venture between SoftBank Group Corp. and Tempus AI, Inc., initiated in June 2024, aimed at developing personalized treatments and clinical trial recommendations. Such activities showcase the government's efforts to enhance the growth and development of the country's healthcare and research sectors and are expected to positively influence the expansion of the Japan immunofluorescence assays market.

Pharmaceutical and Biotechnology Companies Boost Market Expansion

Increasing investments towards pharmaceutical and biotechnology companies is expected to bolster Japan immunofluorescence assays market demand. Immunofluorescence assays play a crucial role in the identification of biomarkers, drug development and discovery, toxicology studies, and quality control activities. Several biotechnology and pharmaceutical companies in the country are engaging in partnerships and collaborations with leading research and academic institutions to bolster the development and availability of novel therapeutic and diagnostic solutions, augmenting the reliance on immunofluorescence assays.

According to the estimates of the Japan Pharmaceutical Manufacturers Association's Data Book for 2024, the ethical drug market in Japan grew from USD 60.6 billion in 2003 to USD 84.23 billion in 2022. Additionally, the growing preference for precision medicine that often requires precise and accurate diagnostic solutions including immunofluorescence assays is also expected to bolster the dependency upon the market.

Cancer Expected to Witness Significant Growth

The rising threat of cancer in the country is propelling the market's demand. As per the estimates of the Organization for Economic Cooperation and Development, one in three premature deaths in Japan will be caused because of cancer between 2023 and 2050. The increasing prevalence of such chronic conditions in the country is propelling the demand for advanced diagnostic solutions for reducing mortality rates by ensuring timely intervention for effective management and treatment of the conditions.

Modern immunofluorescence assays detect various biomarkers simultaneously and ensure the provision of a comprehensive view of the tumors. This capability is especially useful in the field of cancer diagnostics and research as it allows for a detailed analysis of different complex biological samples. Additionally, immunofluorescence assays are also essential for cancer research as they allow researchers to study the localization and expression of proteins within the cancer cells.

Future Market Scenario (FY2025 - FY2032F)

According to Japan immunofluorescence assays market analysis, the market is expected to observe significant growth over the forecast period due to the rapid expansion of the ageing population, the growing threat of infectious and chronic diseases, and increasing investments towards research and development activities. As per an article published in the American Association for Cancer Research (AACR), the prevalence of cancer in Japan is estimated to reach 3,665,900 by 2050.

The rapid expansion of the biotechnology industry coupled with the increasing emphasis on the enhancement of the healthcare infrastructure is also expected to provide lucrative growth opportunities to the market. With increasing requirements for early disease diagnosis and precision medicine, the reliance on immunofluorescence assays will increase significantly in Japan.

The rising efforts of the government to bolster the availability of cost-effective diagnostic solutions to ensure the affordability and accessibility of technologically advanced diagnostic tools will sustain the market's growth over the forecast period.

Key Players Landscape and Outlook

Strategic collaborations between leading scientific institutions in Japan and key players in the market to bolster the development and availability of advanced technologies in the country are providing lucrative growth opportunities to Japan immunofluorescence assays market.

In May 2023, Konica Minolta, Inc. and Japan Bio Measurement & Analysis Consortium (JMAC) announced a proposal for promoting the adoption of advanced technologies that originated in Japan. The novel standards developed along with the Ministry of Economy, Trade and Industry cover indirect immunofluorescence assays with fluorescent nanoparticles that are utilized for labelling molecules that bind to secondary antibodies, including streptavidin. The issued standards standardize the performance evaluation indicators including quantification accuracy verification guidelines, particle size, and detection sensitivity, for protein quantification kits and staining reagents, among others (Konica Minolta's phosphor-integrated dots (PID).

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Japan Immunofluorescence Assays Market Outlook, FY2018-FY2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Products
    • 4.2.1.1. Antibodies
      • 4.2.1.1.1. Primary Antibodies
      • 4.2.1.1.2. Secondary Antibodies
    • 4.2.1.2. Kits and Reagents
      • 4.2.1.2.1. Stains and Dyes
      • 4.2.1.2.2. Media and Sera
      • 4.2.1.2.3. Buffers and Solvents
      • 4.2.1.2.4. Probes
      • 4.2.1.2.5. Other Reagents
    • 4.2.1.3. Instruments
      • 4.2.1.3.1. Image Analysis Systems
      • 4.2.1.3.2. Microscopes
    • 4.2.1.4. Consumables and Accessories
  • 4.2.2. By Type
    • 4.2.2.1. Indirect Immunofluorescence
    • 4.2.2.2. Direct Immunofluorescence
  • 4.2.3. By Application
    • 4.2.3.1. Cancer
    • 4.2.3.2. Infectious Diseases
    • 4.2.3.3. Cardiovascular Diseases
    • 4.2.3.4. Autoimmune Diseases
    • 4.2.3.5. Others
  • 4.2.4. By End-user
    • 4.2.4.1. Academic and Research Institutes
    • 4.2.4.2. Pharmaceutical and Biotechnology Companies
    • 4.2.4.3. Contract Research Organizations
    • 4.2.4.4. Hospitals and Diagnostic Centers
  • 4.2.5. By Region
    • 4.2.5.1. North [Hokkaido and Tohoku]
    • 4.2.5.2. Central [Kanto and Chubu]
    • 4.2.5.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2024)
• 4.3. Market Map Analysis, FY2024
  • 4.3.1. By Products
  • 4.3.2. By Type
  • 4.3.3. By Application
  • 4.3.4. By End-user
  • 4.3.5. By Region

5. Demand Supply Analysis

6. Value Chain Analysis

7. Porter's Five Forces Analysis

8. PESTLE Analysis

9. Pricing Analysis

10. Market Dynamics

• 10.1. Market Drivers
• 10.2. Market Challenges

11. Market Trends and Developments

12. Regulatory Framework and Innovation

• 12.1. Clinical Trials
• 12.2. Regulatory Approvals

13. Patent Landscape

14. Case Studies

15. Competitive Landscape

• 15.1. Competition Matrix of Top 5 Market Leaders
• 15.2. SWOT Analysis for Top 5 Players
• 15.3. Key Players Landscape for Top 10 Market Players
  • 15.3.1. Immuno-Biological Laboratories Co, Ltd.
    • 15.3.1.1. Company Details
    • 15.3.1.2. Key Management Personnel
    • 15.3.1.3. Products and Services
    • 15.3.1.4. Financials (As Reported)
    • 15.3.1.5. Key Market Focus and Geographical Presence
    • 15.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 15.3.2. Euroimmun Japan Co., Ltd.
  • 15.3.3. Thermo Fisher Scientific Inc.
  • 15.3.4. Bio-Rad Laboratories, Inc.
  • 15.3.5. Abcam plc
  • 15.3.6. PerkinElmer Inc.
  • 15.3.7. Merck KGaA
  • 15.3.8. Cell Signaling Technology, Inc.
  • 15.3.9. Danaher Corporation
  • 15.3.10. Sino Biological, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

16. Strategic Recommendations

17. About Us and Disclaimer